Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

BACKGROUND: Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaiswal, Bijay S., Janakiraman, Vasantharajan, Kljavin, Noelyn M., Eastham-Anderson, Jeffrey, Cupp, James E., Liang, Yuxin, Davis, David P., Hoeflich, Klaus P., Seshagiri, Somasekar
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683562/
https://www.ncbi.nlm.nih.gov/pubmed/19492075
http://dx.doi.org/10.1371/journal.pone.0005717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683562/
https://www.ncbi.nlm.nih.gov/pubmed/19492075
http://dx.doi.org/10.1371/journal.pone.0005717

Ejemplares similares